Vladimir Torchilin, PhD
Vladimir P Torchilin is a University Distinguished Professor and Director at the Center for Pharmaceutical Biotechnology and Nanomedicine at the School of Pharmacy, Northeastern University (MA, USA).
Vladimir Torchilin graduated from the Moscow University with an MS in Chemistry and also obtained his PhD and DSc in Polymer Chemistry, Chemical Kinetics and Catalysis, and Chemistry of Physiologically Active Compounds in 1971 and 1980, respectively. In 1991 Dr. Torchilin joined Massachusetts General Hospital and Harvard Medical School as the Head of Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. Since 1998 Dr. Torchilin is with Northeastern University. He was the Chair of the Department of Pharmaceutical Sciences 1998-2007. His research interests have focused on biomedical polymers, polymeric drugs, immobilized medicinal enzymes, drug delivery and targeting, pharmaceutical nanocarriers for diagnostic and therapeutic agents, and experimental cancer immunology. He has published more than 300 original papers, more than 100 reviews and book chapters, wrote and edited 10 books, including Immobilized Enzymes in Mecicine, The Handbook on Targeted Delivery of Imaging Agents, Liposomes: A Practical Approach, Nanoparticulates as Pharmaceutical Carriers, Multifunctional Pharmaceutical Nanocarriers, Biomedical Aspects of Drug Targeting, Delivery of Protein and Peptide Drugs in Cancer, and holds more that 40 patents. He is Editor-in-Chief of Current Drug Discovery Technologies, Co-Editor-in-Chief of Drug Delivery and on the Editorial Boards of many leading journals in the field including Journal of Controlled Release (Review Editor), Bioconjugate Chemistry, Advanced Drug Delivery Reviews, European Journal of Pharmaceutics and Biopharmaceutics, Journal of Drug Targeting, Molecular Pharmaceutics, Journal of Biomedical Nanotechnology, and few others. Among his many awards, Professor Torchilin was the recipient of the 1982 Lenin Prize in Science and Technology (the highest scientific award in the former USSR). He was elected as a Member of European Academy of Sciences. He is also a Fellow of American Institute of Medical and Biological Engineering and of American Association of Pharmaceutical Scientists (AAPS), and received the 2005 Research Achievements in Pharmaceutics and Drug Delivery Award from the AAPS and 2007 Research Achievements Award from the Pharmaceutical Sciences World Congress. In 2005-2006 he served as a President of the Controlled Release Society.
Robert Elfont, MD, PhD
Robert Elfont is a Johns Hopkins-trained neurologist with subspecialty training in neuroimmunology and neurovirology.
He possesses over ten years in the pharmaceutical and biotechnology industry and eight years in academic practice. Dr. Elfont is knowledgeable in all phases of clinical development and he has an extensive expertise in CNS drug development, including neurologic, psychiatric, and pain indications. He has experience with both small molecules and biologics.
Xavier Luria, MD
He has extensive experience in international drug development, in particular clinical, and is a specialist in pharmaceutical medicine.
He has been exposed to this area from a triangle perspective: as a hospital’s medical doctor with postgraduate training in internal medicine, as clinical researcher and management and leadership positions in pharma industry and, finally, as relevant European Medicines Agency (EMA) manager.
He has been extensively involved setting up strategy, design and operations of drug development programs and post-marketing drug surveillance, as well as on portfolio management and in-and-out licensing opportunities.
His competence in drug regulation has been developed through more than 18 years of experience in the pharmaceutical industry dealing with several worldwide regulatory authorities and further 6 years in a regulatory key position at the EMA.